HeyJaredOyvind Dahle
- Indexed articles, last 90 days
- 2
- Latest publication
- Aug 6, 2026
- Outlet visibility, for Mondaq
- Top 500K sites
- Earliest in this view
- Jul 28, 2026
Latest articles
What Counts As Therapeutic Progress And Innovation In Longevity Biotechnology? (opens the original)
Read excerpt
Longevity biotechnology is attracting increasing scientific, commercial, and investor interest. The unprecedented clinical success of GLP-1 on multiple age-associated conditions has prompted some to call it the first longevity drug, which has certainly boosted excitement for longevity biotechnology. However, there are disagreements on some core concepts needed for efficiently translating aging research into clinical treatments and development of longevity drugs. A 2024 PNAS Nexus survey led by V
ER-100: Cellular Reprogramming Meets The Clinic (opens the original)
Read excerpt
The promise of cellular reprogramming has reached the clinic. In a recent Nature article, Heidi Ledford describes Life Biosciences’ ER-100 as a cellular-reprogramming treatment that “aims to rejuvenate damaged cells in the eye.” This first-in-human Phase 1 trial of ER-100 marks the beginning of an important test: can the foundational science of the Yamanaka factors be engineered into a safe, reproducible, and clinically meaningful therapy? The engineering, regulatory, and commercial challenges o
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 500K sites
For Mondaq, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.